Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more


Robinson, J.O. and Christiansen, K. (2017) Gatifloxacin. In: Grayson, M.L., Cosgrove, S.E., Crowe, S.M., Hope, W., McCarthy, J.S., Mills, J., Mouton, J.W. and Paterson, D.L., (eds.) Kucers’ The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs. CRC Press.

Link to Published Version:
*Subscription may be required


Gatifloxacin is an 8-methoxy-fluoroquinolone and is marketed by Bristol Myers Squibb as Tequin, having licensed the medication from the Kyorin Pharmaceutical Company in Japan. It is known by a variety of proprietary names pursuant to the formulation and the country in which it is marketed. Three formulations are available, oral, ophthalmic, and intravenous. Like other members of this class, gatifloxacin has activity against many Gram-positive and Gram-negative bacteria and many intracellular respiratory pathogens. In particular it has activity against penicillin-susceptible and -resistant Streptococcus pneumoniae, methicillin-susceptible Staphylococcus aureus (MSSA), and some anaerobes. Unlike ciprofloxacin it lacks significant activity against Pseudomonas aeruginosa.

Item Type: Book Chapter
Publisher: CRC Press
Other Information: 7th Edition
Item Control Page Item Control Page